Compare HRZN & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRZN | TOI |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | 641 |
| Industry | Finance/Investors Services | Medical/Nursing Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.1M | 512.9M |
| IPO Year | N/A | N/A |
| Metric | HRZN | TOI |
|---|---|---|
| Price | $4.40 | $5.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $6.50 | ★ $6.67 |
| AVG Volume (30 Days) | 839.7K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 33.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.25 | $30.15 |
| Revenue Next Year | $22.53 | $25.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $2.02 |
| 52 Week High | $8.46 | $5.58 |
| Indicator | HRZN | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 50.76 | 67.02 |
| Support Level | $3.93 | $2.91 |
| Resistance Level | $4.74 | N/A |
| Average True Range (ATR) | 0.19 | 0.39 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 55.00 | 78.97 |
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.